Related by context. All words. (Click for frequent words.) 66 relapsed MM 65 neoadjuvant treatment 63 recurrent glioblastoma multiforme 63 cisplatin gemcitabine 63 recurrent GBM 63 randomized multicenter Phase III 63 recurrent metastatic 62 Irinotecan 62 Platinol ® 62 Temsirolimus 62 Cimzia TM 62 DEB# 62 sunitinib malate 62 ATACAND 61 carboplatin paclitaxel 61 zalutumumab 61 comparator arm 61 PEG IFN 61 relapsing multiple sclerosis 61 oral rivaroxaban 61 5-FU/LV 61 goserelin 61 #mg/#mg 61 CLARITY study 61 thalidomide Thalomid 61 ribavirin RBV 61 ER CHOP 61 mycophenolate mofetil MMF 61 mitoxantrone plus 61 CIMZIA TM 61 Neoadjuvant 60 paclitaxel carboplatin 60 GW# [003] 60 CHAMPION PCI 60 FOLFIRI 60 Adjuvant chemotherapy 60 salmeterol fluticasone 60 alfa 2a 60 biliary tract cancer 60 Folfox 60 MAGE A3 ASCI 60 stage IIIb IV 60 plus gemcitabine 60 Acute Coronary Syndromes ACS 60 heavily pretreated patients 60 metastatic malignant 60 anthracyclines taxanes 60 rFSH 60 immunomodulatory therapy 60 clevidipine 60 doxorubicin cyclophosphamide 60 sorafenib Nexavar 60 anthracycline taxane 60 gemcitabine cisplatin 60 partial remissions 60 Cloretazine 60 Rituxan rituximab 60 paclitaxel poliglumex 60 CRp 60 abiraterone acetate 60 pegylated interferon alfa 2b 60 eflornithine 60 ritonavir boosted atazanavir 59 paclitaxel Taxol R 59 dalteparin 59 pegylated liposomal doxorubicin 59 Dyloject TM 59 BRAF inhibitor 59 MGd 59 bacillus Calmette Guerin 59 FUSILEV enhances 59 low dose cytarabine 59 fluorouracil 59 axitinib 59 lenalidomide Revlimid R 59 FOLFOX4 59 Femara letrozole 59 HCV RESPOND 2 59 pomalidomide 59 mg/m2 dose 59 mitoxantrone chemotherapy 59 estramustine 59 ritonavir boosted 59 ZACTIMA 59 Tarceva TM 59 beta 1a 59 Pegylated Liposomal Doxorubicin 59 refractory metastatic 59 Xelox 59 Doxil ® 59 FOLPI 59 Amrubicin 59 chemoradiation therapy 59 refractory indolent non 59 Unstable Angina 59 mycophenolate mofetil 59 Fludarabine 59 metastatic malignant melanoma 59 ZOLINZA 59 doxorubicin docetaxel 59 bendamustine 59 Pivotal Phase III 59 docetaxel Taxotere ® 59 prednisone prednisolone 59 chemotherapy cisplatin 59 Flu Cy 59 pertuzumab 59 dose melphalan 59 cyclophosphamide methotrexate 59 Bosutinib 59 glufosfamide 59 regorafenib 59 concurrent chemoradiation 59 ara C 59 Campath alemtuzumab 59 vismodegib 59 melphalan prednisone 59 Dasatinib 59 histologically confirmed 59 dasatinib Sprycel ® 59 pregabalin Lyrica 59 Epirubicin 59 4mg/kg 59 Aptivus ® 59 TAXOTERE R 59 recovery CRp 59 Pemetrexed 59 phase IIIb 58 Darusentan 58 epoetin alpha 58 forodesine 58 acyclovir Lauriad R 58 Stage IIB 58 blinded randomized placebo controlled 58 #mg/m# [001] 58 basal cell carcinoma BCC 58 vandetanib 58 standard chemotherapy regimens 58 nonmetastatic 58 CAELYX 58 BR.# 58 IFN alfa 58 Elitek 58 TPV r 58 refractory chronic lymphocytic 58 DOXIL 58 interferon alfa 2a 58 assessing T DM1 58 Pimavanserin 58 Bevacizumab Avastin 58 CR nPR 58 haematologic 58 fluvastatin 58 biochemical relapse 58 Pharmacokinetics PK 58 taxotere 58 adalimumab Humira 58 dacarbazine chemotherapy 58 dosing cohorts 58 CIMZIA ™ 58 Alkeran 58 Pegasys ® 58 dacarbazine DTIC 58 TMC# r 58 azilsartan medoxomil 58 ACTEMRA TM 58 Follicular Lymphoma 58 antiretroviral naïve 58 YONDELIS 58 neoadjuvant chemotherapy 58 FOLFOX6 58 idiopathic thrombocytopenic purpura ITP 58 galiximab 58 nab paclitaxel 58 trastuzumab Herceptin ® 58 BARACLUDE ® 58 CIMZIA TM certolizumab pegol 58 8mg/kg 58 FOLFIRI alone 58 #mg QD [002] 58 superficial bladder cancer 58 Cyclophosphamide 58 riociguat 58 nadolol 58 temsirolimus 58 Stage IIIb 58 oral ridaforolimus 58 Teriflunomide 58 interferon ribavirin 58 demonstrated antitumor activity 58 Alocrest 58 postoperative chemotherapy 58 Panzem R NCD 58 genotypic resistance 58 Toxicities 58 ChronVac C R 58 gemcitabine carboplatin 58 Phase Ib clinical 58 vidofludimus 58 external beam radiotherapy 58 AMEVIVE 58 5 fluorouracil leucovorin 58 Gleevec imatinib mesylate 58 rFVIIa 58 Melphalan 58 docetaxel Taxotere 58 dexamethasone Decadron 58 receptor tyrosine kinase inhibitor 58 CCyR 58 administered subcutaneously 58 cetuximab Erbitux ® 58 neurologic progression 58 corifollitropin alfa 58 Fluorouracil 58 Aflibercept 58 resminostat 58 PEGylated interferon beta 1a 58 debulking surgery 58 cidofovir 58 cisplatin chemotherapy 57 infusional 57 dose escalation phase 57 acute GvHD 57 visilizumab 57 peginterferon alpha 2a 57 sorafenib Nexavar ® 57 pegylated interferon alfa 57 eosinophilic asthma 57 epirubicin cyclophosphamide 57 candidates Dyloject TM 57 active comparator 57 cyclophosphamide doxorubicin vincristine 57 progression TTP 57 sunitinib Sutent 57 Peg IFN 57 placebo controlled clinical 57 Nexavar sorafenib 57 nucleotide analogue 57 abacavir Ziagen 57 NMIBC 57 advanced pancreatic neuroendocrine 57 Peginterferon 57 irbesartan 57 eribulin mesylate 57 Bezielle 57 HER2 positive metastatic breast 57 octreotide LAR 57 Topotecan 57 leukotriene receptor antagonist 57 iniparib 57 metastatic CRC 57 VNP#M 57 PegIFN 57 dosing cohort 57 Vidaza azacitidine 57 Onrigin 57 T1c 57 huN# DM1 57 gastrointestinal stromal tumors GIST 57 pegylated interferon alfa 2a 57 Cloretazine ® 57 RhuDex TM 57 induce remission 57 intra arterial chemotherapy 57 phase IIb clinical 57 Lenalidomide 57 investigational protease inhibitor 57 omacetaxine mepesuccinate 57 BRIM2 57 Zemplar 57 APTIVUS R 57 ARCOXIA 57 zidovudine lamivudine 57 unresectable HCC 57 REMINYL ® 57 Ixempra 57 transarterial 57 Triapine R 57 epirubicin 57 OvaRex 57 MabCampath 57 LCP Tacro TM 57 cancer mCRC 57 flutamide 57 heFH 57 RhuDex R 57 AIR CF1 57 Systemic Sclerosis 57 gemcitabine Gemzar ® 57 alpha 2a 57 Accelerated Partial Breast Irradiation 57 phase IIa clinical 57 irinotecan chemotherapy 57 desvenlafaxine succinate 57 zonisamide SR 57 Bayer HealthCare Onyx Pharmaceuticals 57 Belatacept 57 Noxafil 57 metastatic renal cell carcinoma 57 GRNVAC1 57 FOLFOX 57 mapatumumab 57 nadroparin 57 icatibant 57 remission induction 57 methotrexate therapy 57 erlotinib Tarceva ® 57 fludarabine cyclophosphamide 57 corticosteroid therapy 57 ixabepilone 57 non resectable 57 Tykerb lapatinib 57 Exemestane 57 platelet inhibitor 57 tolevamer 57 chemoradiotherapy 57 somatostatin analog 57 locoregional recurrence 57 intravenous dosing 57 FOLFOX chemotherapy 57 mg administered orally 57 CLL SLL 57 myeloablative 57 cediranib 57 adjuvant cisplatin 57 PegIFN RBV 57 immunoconjugate 57 Patients Treated With 57 CHOP chemotherapy 57 RE LY 57 gemcitabine Gemzar 57 VELCADE melphalan 57 paclitaxel Taxol ® 57 alefacept 57 docetaxel chemotherapy 57 Cardiotoxicity 57 de novo kidney transplant 57 PTK# 57 Tacrolimus 57 Nilotinib 57 protease inhibitor PI 57 locoregional 57 phase IIb study 57 daunorubicin 57 BoNTA 57 Ziprasidone 57 placebo dexamethasone 57 Ranibizumab 57 Gemzar gemcitabine 57 Interferon alfa 57 Velcade bortezomib 57 Degarelix 57 Cytoxan 56 androgen suppression 56 Brinavess 56 Azacitidine 56 TEMODAL 56 radiotherapy RT 56 Retreatment 56 abatacept Orencia 56 Prolongs Survival 56 Torisel 56 certolizumab 56 budesonide pMDI 56 MVA MUC1 IL2 56 endoscopic remission 56 chemotherapy docetaxel 56 paclitaxel Taxol 56 bevacizumab Avastin ® 56 Surgical resection 56 immunotherapeutic vaccine 56 generation purine nucleoside 56 cetuximab Erbitux R 56 adjuvant radiotherapy 56 topically administered 56 ASCT 56 nicardipine 56 rituximab Rituxan 56 Pegasys plus Copegus 56 samalizumab 56 AGILECT R 56 Abiraterone Acetate 56 pamidronate 56 Phase IIb clinical trials 56 null responder HCV 56 Telcyta 56 Zytiga 56 TTF Therapy 56 Phase IIIb clinical 56 tamoxifen Nolvadex ® 56 liver metastasis 56 unfractionated heparin UFH 56 bortezomib Velcade 56 saline placebo 56 HBeAg + 56 GOUT 56 investigational antiplatelet agent 56 plus dexamethasone 56 standard chemotherapy regimen 56 HBeAg positive patients 56 miconazole Lauriad ® 56 boosted protease inhibitor 56 ELACYT 56 allogeneic hematopoietic stem cell 56 cilengitide 56 GP IIb IIIa inhibitors 56 ENGAGE AF TIMI 56 #mg dosing group 56 KAPIDEX 56 refractory AML 56 randomized Phase IIb 56 DMARD therapy 56 pegylated interferon alpha 56 steroid refractory 56 paclitaxel cisplatin 56 Fingolimod 56 Hormone Refractory Prostate Cancer 56 Pegylated Interferon 56 Acute Decompensated Heart Failure 56 oral methylnaltrexone 56 Mycophenolate Mofetil 56 RezularTM 56 SPRYCEL ® 56 unresectable tumors 56 unresectable stage 56 RELOVAIR ™ 56 refractory CLL 56 Zybrestat 56 cytoreduction 56 KRAS mutations occur 56 OvaRex MAb 56 achieved CCyR 56 BRIM3 56 Hazard Ratio 56 teriflunomide 56 oblimersen 56 trastuzumab Herceptin R 56 IMPACT DCM 56 mg BID 56 BENICAR 56 raloxifene Evista 56 bolus dose 56 CALGB # [002] 56 chlorambucil 56 mitoxantrone 56 Phase 2a trial 56 Myelodysplastic Syndrome MDS 56 carmustine 56 Severe Sepsis 56 intratympanic 56 tenofovir FTC 56 Fludara ® 56 recurrent malignant glioma 56 intermittent dosing 56 BCG refractory 56 IV bolus 56 Taxotere docetaxel 56 bevacizumab Avastin 56 patientswith 56 alemtuzumab Campath 56 metastatic pancreatic 56 mitomycin 56 Initiates Phase 2b 56 DU #b 56 Investigational Treatment 56 glycoprotein IIb IIIa inhibitor 56 ascending doses 56 Proellex TM 56 Platinol ® cisplatin 56 5 Fluorouracil 56 EOquin TM 56 q#h 56 Gemcitabine 56 Vernakalant 56 BCR ABL inhibitor 56 Quinamed 56 paliperidone ER 56 vincristine doxorubicin 56 PPAR gamma agonist 56 Targretin capsules 56 completely resected 56 temozolomide TMZ 56 Vfend 56 mcg doses 56 lopinavir r 56 thorough QT 56 trastuzumab DM1 56 lenalidomide dexamethasone 56 Trastuzumab 56 leukemia AML 56 Dacogen injection 56 VFEND 56 Viread Emtriva 56 aspirin clopidogrel 56 weekly subcutaneous injections 56 capecitabine Xeloda 56 etanercept Enbrel 56 erythropoietic 56 Phase IIA 56 #mg/day [001] 56 efficacy endpoint 56 palifermin 56 clinically evaluable 56 lymphoproliferative disorders 56 untreated multiple myeloma 56 senicapoc 56 adjuvant therapy 56 plus prednisone prednisolone 56 adjuvant tamoxifen 56 relapsed refractory 56 recurrent DVT 56 PF # [002] 56 dacarbazine 56 risperidone Risperdal 56 visceral metastases 56 Fludara 56 tumor lysis syndrome 56 benign prostatic hypertrophy BPH 56 Laquinimod 56 dose regimens 56 ELOXATIN 56 CALGB 56 evaluating tivozanib 56 essential thrombocythemia ET 56 Advagraf 56 baminercept 56 peg interferon 56 hormone refractory metastatic prostate 56 Multiple Ascending Dose 56 ethambutol 56 NSABP B 56 mucosal healing 56 PANVAC VF 56 aflibercept 56 Omnitarg 56 subcutaneous SC 56 stage IIIB 55 corticosteroid dexamethasone 55 ISTODAX ® 55 ACE Inhibitor 55 TMP SMX 55 evaluating Prochymal 55 Phase Ib Clinical Trial 55 underwent resection 55 novel oral anticoagulant 55 mCRC patients 55 lumiliximab 55 neoadjuvant therapy 55 Tyrosine Kinase Inhibitors 55 null responder 55 neratinib 55 Metastatic Colorectal Cancer 55 LYSTEDA 55 PSMA ADC 55 pegylated liposomal doxorubicin PLD 55 oral clodronate 55 Alemtuzumab 55 β blockers 55 zoledronic acid Reclast 55 ulcerative colitis UC 55 PREZISTA ritonavir 55 metastatic HER2 positive 55 OvaRex ® MAb 55 Dose Ranging Study 55 cabazitaxel 55 HCV SPRINT 55 serotonin norepinephrine reuptake inhibitor 55 Recurrent Glioblastoma 55 STELARA ™ 55 interferon beta 1b 55 TURBT 55 ß blockers 55 interferon lozenges 55 heavily pretreated 55 refractory colorectal cancer 55 Carvedilol 55 IV NSCLC 55 divalproex sodium 55 velafermin 55 methotrexate monotherapy 55 Fulvestrant 55 Gliadel Wafer 55 evaluating mipomersen 55 olmesartan 55 Dacogen decitabine 55 octreotide 55 dose escalation clinical 55 Phase #b/#a clinical 55 Taxol paclitaxel 55 #mg ATC 55 clodronate 55 Phase Ib II 55 GVAX 55 ruboxistaurin 55 StemEx 55 Arranon 55 CANCIDAS 55 Combination REOLYSIN R 55 CRLX# 55 Soft Tissue Sarcoma 55 CAMMS# 55 dosing intervals 55 #mg BID [001] 55 #mg BID [003] 55 achieved ACR# 55 ibandronate 55 tipranavir r 55 Glatiramer acetate 55 piperacillin tazobactam 55 interferon alfa 2b 55 androgen blockade 55 Meets Primary Endpoint 55 Erlotinib 55 inhaled treprostinil 55 intradermal injections 55 Posaconazole 55 mg/m2/day 55 stage IIIB IV 55 APTIVUS r 55 Phase 2b Clinical Trial 55 biologic therapy 55 mRCC 55 octreotide acetate 55 MCyR 55 CHARM Added 55 subcutaneous enoxaparin 55 #mg QD [001] 55 Advaxis Phase 55 Paraplatin ® 55 decitabine 55 Pertuzumab 55 metastatic GIST 55 remission CR 55 lenalidomide Revlimid 55 gadobutrol 55 tipranavir 55 measurable tumor regressions 55 MEND CABG 55 adriamycin 55 HuMax EGFr 55 Gleevec imatinib 55 Anthracycline 55 GSK# [001] 55 chronic GVHD 55 Partial Response 55 cytogenetic response 55 papillary renal cell carcinoma 55 pharmacokinetic PK study 55 Ocrelizumab 55 histologically proven 55 anthracycline containing 55 patients evaluable 55 beclomethasone dipropionate 55 CR CRu 55 TLK# 55 Mitoxantrone 55 neoadjuvant 55 azacitidine 55 liver resection 55 busulfan 55 Toremifene 55 DCVax ® Brain 55 recurrent epithelial ovarian 55 severe oral mucositis 55 Navelbine ® 55 denileukin diftitox 55 Omacetaxine 55 intravenous bisphosphonates 55 daily subcutaneous injections 55 tumors GIST 55 metastatic gastric 55 amoxicillin clavulanate 55 hematologic toxicity 55 Hematologic 55 imiquimod cream 55 Patients Receiving 55 smoldering myeloma 55 recurrent NSCLC 55 Riluzole 55 multicenter phase 55 oral levofloxacin 55 iniparib BSI 55 RECORD1 55 plus prednisone 55 oral anticoagulant therapy 55 antiarrhythmic drugs 55 undetectable HBV DNA 55 administered intranasally 55 Xanafide 55 alkylating agent 55 phase IIb trial 55 Neulasta ® 55 Lapatinib 55 rALLy clinical trial 55 calcineurin inhibitor 55 adverse cytogenetics 55 Tarceva erlotinib 55 vinorelbine tartrate 55 pharmacologically active isomer 55 Lamotrigine 55 cytotoxic therapy 55 metastatic colorectal carcinoma 55 bolus injection 55 5FU 55 hA# 55 Peginterferon alfa 2b 55 potentially hepatotoxic 55 antithymocyte globulin 55 pazopanib 55 LEXIVA r 55 AVOREN 55 virologic failure 55 macrolide antibiotic 55 randomized multicenter trial 55 immunosuppressive regimen 55 thrombocytopenic 55 phase IIa 55 ribavirin therapy 55 mertansine 55 Bevacizumab 55 FluCAM 55 Kepivance 55 IL# PE#QQR 55 Orally administered 55 subcutaneously administered 55 abacavir lamivudine 55 docetaxel Taxotere R 55 cathepsin K inhibitor 55 MIRCERA 55 gefitinib Iressa 55 ximelagatran 55 FIRMAGON 55 treatment naive genotype 55 pegylated interferon alpha 2a 55 Herceptin trastuzumab 55 Erbitux cetuximab 55 Telintra 55 PREZISTA r 55 advanced hepatocellular carcinoma 55 DOXIL ® 55 acromegalic patients 55 cranial irradiation 55 dose dexamethasone 55 gamma secretase inhibitor 55 darunavir r 55 HCV Genotype 55 dose titration 55 myelodysplastic myeloproliferative diseases 55 canakinumab 55 maximally tolerated dose 55 depsipeptide 55 refractory NSCLC 55 Phase IIIb study 55 chemotherapeutic regimen 55 subcutaneous formulation 55 Q#IR 55 Infliximab 55 Chemophase 55 tenofovir emtricitabine 55 INSPIRE Trial Phase III 55 AVONEX ® 55 levosimendan 55 peginterferon alfa 55 APTIVUS 55 severe exacerbations 55 phase Ib 55 efavirenz EFV 55 Vidofludimus 55 clopidogrel Plavix 55 Phase III placebo controlled 55 Hycamtin 55 tolvaptan 55 metastatic HRPC 55 RRMS patients 55 telaprevir dosing 55 PEGINTRON TM 55 advanced medullary thyroid 55 DAPT 55 hepatic metastases 55 bevacizumab Avastin R 55 Febuxostat 55 infusional 5-FU/LV 55 TAXOTERE ® 55 PDE4 inhibitor 55 Myelofibrosis 55 Lucanix 54 multicenter randomized controlled 54 midstage clinical 54 GAMMAGARD 54 adjuvant colon cancer 54 RhuDex ™ 54 talabostat 54 paricalcitol 54 Zolinza 54 Patency 54 Renal Cell Carcinoma RCC 54 GetGoal Phase III 54 BCIRG 54 polycythemia vera essential thrombocythemia 54 adjunctive placebo 54 HBeAg negative patients 54 Acute Ischemic Stroke 54 Forodesine HCl 54 ABVD 54 Onconase 54 hormone receptor negative 54 lymphocyte count 54 mg q8h 54 dorzolamide 54 ACEI 54 pharmacodynamic PD 54 Pegasys peginterferon alfa 2a 54 LHRH receptor positive 54 IMA# 54 otamixaban 54 PEG Interferon 54 dosage regimens 54 intravesical chemotherapy 54 gemtuzumab ozogamicin 54 PROCHYMAL 54 Telithromycin 54 rALLy 54 Neuvenge 54 EBRT 54 #mg/m# [002] 54 Cancidas 54 Merck KGaA Erbitux 54 prior chemotherapy regimens 54 MEND CABG II 54 aliskiren amlodipine 54 CYT# potent vascular disrupting 54 cyclophosphamide FC 54 HCV Protease Inhibitor 54 allogeneic HSCT 54 Sprycel dasatinib 54 MNTX 54 Aquavan 54 ABSORB trial 54 Eraxis 54 metastatic bone 54 Vicinium TM 54 pT2 54 Relapsing remitting MS 54 beta2 agonist 54 Gleevec resistant 54 nonsmall cell lung cancer 54 fluoropyrimidine 54 DMARDS 54 pT3 54 immunomodulatory agents 54 prospectively defined 54 azacytidine 54 nilotinib Tasigna ® 54 endothelin receptor antagonists 54 fluorouracil leucovorin 54 Trandolapril 54 clomipramine 54 EGFR mutation positive 54 relapsed ovarian cancer 54 docetaxel prednisone 54 FOLFOX regimen 54 intravenous cyclophosphamide 54 bortezomib Velcade R 54 everolimus tablets 54 dimeglumine 54 Protease Inhibitors 54 oral deforolimus 54 dose cohorts 54 superficial basal cell carcinoma 54 CINTREDEKIN BESUDOTOX 54 insulin glulisine 54 adefovir dipivoxil 54 Simulect 54 fosbretabulin 54 interstitial brachytherapy 54 nalbuphine 54 intradermal injection 54 recurrent glioma 54 seropositive patients 54 cefazolin 54 aflibercept VEGF Trap 54 injected subcutaneously 54 recurrent herpes labialis 54 Initiate Phase 54 imatinib Gleevec ® 54 Celebrex celecoxib 54 gemcitabine chemotherapy 54 pain palliation 54 autologous SCT 54 inhaled corticosteroid ICS 54 relapsed CLL 54 MIVI TRUST 54 disease progression TTP 54 trabectedin 54 Bayer Onyx 54 antiandrogen 54 tocilizumab 54 Taxotere ® 54 eculizumab therapy 54 XELOX 54 ® lenalidomide 54 dose cohort 54 INVEGA ® 54 dasatinib 54 Phase IIB 54 monoclonal antibody conjugated 54 IRX 2 54 Capesaris 54 inhibitor RG# 54 hydrochloride capsules 54 serine protease inhibitor 54 Heterozygous Familial Hypercholesterolemia 54 Allovectin 7 ® 54 randomized blinded 54 Cutaneous T 54 recurrent glioblastoma 54 cilostazol 54 FASLODEX 54 lymphoid malignancies 54 lorvotuzumab mertansine 54 elotuzumab 54 Newly Diagnosed Multiple Myeloma 54 surgical debulking 54 taxane therapy 54 ipsilateral breast 54 BrachySil TM 54 panitumumab Vectibix 54 Free Survival PFS 54 conventional DMARDs 54 Anthim 54 elacytarabine 54 HCl capsules 54 placebo controlled Phase III 54 mesalamine granules 54 TEMSO 54 Zarnestra 54 lanreotide 54 preoperative chemotherapy 54 bicifadine 54 Investigational Oral 54 nitrofurantoin 54 NSTEMI 54 adjuvant endocrine therapy 54 double blinded randomized 54 Sutent sunitinib 54 randomized #:#:# 54 Alequel 54 OHR/AVR# 54 pegylated interferon peg IFN 54 Vidaza R 54 Hepatotoxicity 54 trastuzumab Herceptin 54 prospective nonrandomized 54 fludarabine 54 PEG SN# 54 hyaluronidase enzyme 54 Phase IIb III 54 MabThera Rituxan 54 decompensated liver disease 54 YONDELIS R 54 Primary endpoints 54 fallopian tube cancers 54 mg/m2 IV 54 prasugrel Effient 54 Phase III randomized controlled 54 rufinamide 54 prospective multicenter 54 FOLFOX6 chemotherapy regimen 54 cardiovascular calcification 54 antiepileptics 54 radiolabeled TM# 54 Triapine 54 inhalation powder 54 darunavir ritonavir 54 bronchial thermoplasty 54 Inhaled nitric oxide 54 tacrolimus ointment 54 recurrent glioblastoma multiforme GBM 54 Dabigatran 54 infliximab Remicade 54 Fondaparinux 54 Zyclara 54 Adrenomyeloneuropathy AMN 54 nitazoxanide 54 epirubicin cisplatin 54 Gilead Viread 54 lupus nephritis 54 Bucindolol 54 complete cytogenetic response 54 receiving highly emetogenic 54 Metastatic Melanoma 54 interferon gamma 1b 54 unstable angina UA 54 HSCT 54 Median PFS 54 MDS AML 54 Safinamide 54 double blinded placebo 54 deferiprone